ATE220400T1 - Trizyklische verbindungen zur behandlung von zellproliferativen störungen - Google Patents
Trizyklische verbindungen zur behandlung von zellproliferativen störungenInfo
- Publication number
- ATE220400T1 ATE220400T1 AT96911439T AT96911439T ATE220400T1 AT E220400 T1 ATE220400 T1 AT E220400T1 AT 96911439 T AT96911439 T AT 96911439T AT 96911439 T AT96911439 T AT 96911439T AT E220400 T1 ATE220400 T1 AT E220400T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cell proliferative
- proliferative disorders
- tricyclic compounds
- cells
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41898295A | 1995-04-07 | 1995-04-07 | |
| PCT/US1996/004168 WO1996031111A1 (en) | 1995-04-07 | 1996-04-03 | Tricyclic compounds useful in the treatment of cell proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE220400T1 true ATE220400T1 (de) | 2002-07-15 |
Family
ID=23660318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96911439T ATE220400T1 (de) | 1995-04-07 | 1996-04-03 | Trizyklische verbindungen zur behandlung von zellproliferativen störungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5891872A (de) |
| EP (1) | EP0819128B1 (de) |
| JP (1) | JPH11503157A (de) |
| AT (1) | ATE220400T1 (de) |
| AU (1) | AU5432596A (de) |
| CA (1) | CA2217680A1 (de) |
| DE (1) | DE69622265T2 (de) |
| ES (1) | ES2175087T3 (de) |
| IL (1) | IL117782A0 (de) |
| MX (1) | MX9707732A (de) |
| WO (1) | WO1996031111A1 (de) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410534B1 (en) | 1998-07-02 | 2002-06-25 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CA2336054A1 (en) | 1998-07-02 | 2000-01-13 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2001227756A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2001051126A1 (en) | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6350755B1 (en) | 2000-01-12 | 2002-02-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6610722B2 (en) | 2000-04-10 | 2003-08-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2005017160A2 (en) | 2003-08-13 | 2005-02-24 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법 |
| US7943622B2 (en) * | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2937345B1 (de) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Typ-ii-raf-kinase-hemmer |
| BR112012023021A2 (pt) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| AP2013007331A0 (en) | 2011-06-24 | 2013-12-31 | Amgen Inc | TRPM8 antagonists and their use in treatments |
| EP2723718A1 (de) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8-antagonisten und ihre verwendung bei behandlungen |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| CN103626761B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2909194A1 (de) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Hemmer der cyclinabhängigen kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017074914A1 (en) * | 2015-10-29 | 2017-05-04 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CN111902401B (zh) * | 2018-02-23 | 2023-06-13 | 北京泰德制药股份有限公司 | 受体抑制剂、包含其的药物组合物及其用途 |
| EP3810132A4 (de) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Kinaseinhibitoren der taire und ihre verwendungen |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (de) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Hemmer der cyclinabhängigen kinase 7 und verwendungen davon |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
| DE212025000115U1 (de) | 2024-07-30 | 2026-06-18 | Sairopa B.V. | Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| US4355036A (en) * | 1980-06-19 | 1982-10-19 | Schering Corporation | Tricyclic-substituted piperidine antihistamines |
| US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US5104876A (en) * | 1988-04-28 | 1992-04-14 | Schering Corporation | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
| MY106964A (en) * | 1988-04-28 | 1995-08-30 | Schering Corp | Fused polycyclic compounds, compositions, methods of manufacture, and their use as paf antagonists, antihistamines and/or antiinflammatory agents. |
| US4863931A (en) * | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
| US6083917A (en) * | 1990-04-18 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification, characterization and inhibition of farnesyltransferase |
| NZ238629A (en) * | 1990-06-22 | 1993-09-27 | Schering Corp | Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation |
| DE69120430D1 (de) * | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
| JPH04356466A (ja) * | 1991-01-28 | 1992-12-10 | Mitsui Toatsu Chem Inc | 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤 |
| US5340828A (en) * | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| CA2165176A1 (en) * | 1993-06-18 | 1995-01-05 | Samuel L. Graham | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-05-22 US US08/446,980 patent/US5891872A/en not_active Expired - Fee Related
-
1996
- 1996-04-02 IL IL11778296A patent/IL117782A0/xx unknown
- 1996-04-03 WO PCT/US1996/004168 patent/WO1996031111A1/en not_active Ceased
- 1996-04-03 DE DE69622265T patent/DE69622265T2/de not_active Expired - Fee Related
- 1996-04-03 JP JP8530360A patent/JPH11503157A/ja not_active Ceased
- 1996-04-03 ES ES96911439T patent/ES2175087T3/es not_active Expired - Lifetime
- 1996-04-03 EP EP96911439A patent/EP0819128B1/de not_active Expired - Lifetime
- 1996-04-03 MX MX9707732A patent/MX9707732A/es not_active IP Right Cessation
- 1996-04-03 CA CA002217680A patent/CA2217680A1/en not_active Abandoned
- 1996-04-03 AT AT96911439T patent/ATE220400T1/de not_active IP Right Cessation
- 1996-04-03 AU AU54325/96A patent/AU5432596A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0819128B1 (de) | 2002-07-10 |
| IL117782A0 (en) | 1996-08-04 |
| ES2175087T3 (es) | 2002-11-16 |
| MX9707732A (es) | 1997-12-31 |
| WO1996031111A1 (en) | 1996-10-10 |
| AU5432596A (en) | 1996-10-23 |
| DE69622265D1 (de) | 2002-08-14 |
| JPH11503157A (ja) | 1999-03-23 |
| US5891872A (en) | 1999-04-06 |
| EP0819128A1 (de) | 1998-01-21 |
| CA2217680A1 (en) | 1996-10-10 |
| DE69622265T2 (de) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622265D1 (de) | Trizyklische verbindungen zur behandlung von zellproliferativen störungen | |
| IL117799A0 (en) | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| MX9707665A (es) | Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas. | |
| MX9707197A (es) | Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas. | |
| ZA947969B (en) | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| MY114132A (en) | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases. | |
| CA2216163A1 (en) | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| ATE71629T1 (de) | Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels. | |
| ATE256667T1 (de) | Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen | |
| MY143570A (en) | Compounds useful for inhibition of farnesyl protein transferase | |
| DE69926078D1 (en) | Farnesyl-protein transferase inhibitoren | |
| DE68926222D1 (de) | Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen | |
| ATE240313T1 (de) | Tricyclische n-cyanoimine als inhibitoren der farnesyl-protein transferase | |
| CA2293713A1 (en) | Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase | |
| CA2293553A1 (en) | Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |